MAT2A Inhibitor

A MAT2A inhibitor is a type of targeted cancer drug that blocks the enzyme methionine adenosyltransferase 2A (MAT2A). This enzyme produces SAM (S-adenosylmethionine), a molecule that certain tumors depend on for survival when they have lost a gene called MTAP. Because many mesotheliomas have lost MTAP, MAT2A inhibitors are being studied as a way to selectively kill mesothelioma cells while sparing normal cells.

Origin

The strategy emerged in the late 2010s after researchers discovered that tumors with MTAP deletion accumulate a metabolite (MTA) that makes them unusually sensitive to MAT2A and PRMT5 inhibition. The first MAT2A inhibitors, including AG-270 (later IDE397) and AGI-25696, entered clinical trials around 2019–2021 for MTAP-deleted cancers, including mesothelioma.

Significance in Asbestos Context

Roughly half of pleural mesotheliomas have a deletion in the CDKN2A region of chromosome 9p21, and that deletion almost always takes the neighboring MTAP gene with it. This makes MAT2A inhibitors one of the more promising targeted therapy approaches specifically for mesothelioma patients. If your tumor has been tested and shown to be MTAP-deficient (by FISH, next-generation sequencing, or immunohistochemistry), you may be eligible for clinical trials of MAT2A inhibitors, often combined with PRMT5 inhibitors. Patients should ask their oncologist whether MTAP testing has been done on their tumor and whether trials of MAT2A or PRMT5 inhibitors are open at their center or at a mesothelioma specialty program.

Example Sentence

After her mesothelioma progressed on chemotherapy, the oncologist ordered MTAP testing and found her tumor was MTAP-deleted, making her a candidate for a clinical trial of a MAT2A inhibitor.

Related Terms

MTAP Deletion, CDKN2A, PRMT5 Inhibitor, Targeted Therapy, Clinical Trial, Mesothelioma

Notes

• Ask your oncologist whether your tumor has been tested for MTAP loss. This is typically done by immunohistochemistry (IHC), FISH, or as part of a next-generation sequencing panel.
• If MTAP is lost, ask specifically about open clinical trials of MAT2A inhibitors (such as IDE397) and PRMT5 inhibitors (such as MRTX1719 or AMG 193). Mesothelioma specialty centers are the most likely sites.
• Keep copies of all molecular pathology and biomarker reports; these documents establish trial eligibility and may also support the medical record in your legal claim by confirming the diagnosis and tumor biology.
• MAT2A inhibitors are investigational. They aren't yet FDA-approved for mesothelioma, so access is generally through clinical trials.